Studies of pembrolizumab have shown promising antitumor activity across a wide cohort of patients with clear cell renal cell carcinoma (ccRCC). The results of a recent study, named…
In this webinar hosted by the Dana-Farber Cancer Institute, Lowe Center for Thoracic Oncology, Pasi Jänne, MD, PhD, Julia Rotow, MD, and Mark Awad, MD, PhD, discuss how…
Courtney D. DiNardo, MD, clinical researcher in the Department of Leukemia, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, discusses how potential doublet…
A research collaboration between Georgia Tech and Emory University, with funding from the National Institutes of Health and the National Science Foundation, studied the effects of hydroxychloroquine (HCQ)…
A study composed of patients from across the USA and Europe observed improved outcomes in those treated with both ilixadencel and sunitinib compared with sunitinib alone. here.
In this interview, David Polsky, MD, PhD, shares details about his advanced laboratory tumor detection technology and the study results presented at ASCO 2020. Dr. Polsky suggests that…
Rogerio C. Lilenbaum, MD, director of the Banner MD Anderson Cancer Center, discusses the ways physicians practicing in different care institutions order molecular panels for patients with nonsquamous…
Rajneesh Nath, MD, medical oncologist at the Banner MD Anderson Cancer Center, discusses early results from the phase 3 SIERRA trial investigating the efficacy of Iomab-B and protocol-specified…
Based on results from an earlier study led by Dr Isamu Okamoto of the Graduate School of Medical Sciences at Kyushu University in Fukuoka, Japan that found progression-free…
Doctors Drilon, Rotow, Stinchcombe, and Saxena participated in a roundtable discussion about therapies targeting certain biomarkers in patients with non-small cell lung cancer (NSCLC). The expert panel agrees…
